Current Position：Home Page > Press Releases
BeBetter Med’s BEBT-209 Approved for Phase III Clinical Trials
2021-12-20 Source：BeBetter Med
On December 18, 2021, the National Center for Drug Evaluation (CDE) approved Guangzhou BeBetter Med Inc. to develop BEBT-209 combined with Fulvestrant in the treatment of HR+/HER2- advanced breast cancer III Phase III clinical trial, titled "BEBT-209 in combination with Fulvestrant in the treatment of HR+/HER2- locally advanced or advanced metastatic breast cancer with disease progression after prior endocrine therapy, a multicenter, randomized, controlled, double-blind phase III clinical study”. This study was led by the Cancer Hospital of the Chinese Academy of Medical Sciences, and led by the team of Academician Xu Binghe, and has passed the ethics review of the hospital.
Related News
- BEBT-503 Passes Phase I Clinical Trial in Australia, Marking a Milestone in BeBe...
- BeBetter Med’s Pan-mutant EGFR Inhibitor BEBT-109 Phase III Clinical Trial Appl...
- BeBetter Med’s First-in-Class New Drug BEBT-908 NDA Accepted
- BeBetter Med Inc. successfully holds the sponsors meeting & the first general me...
- BeBetter Med’s BEBT-209 Approved for Phase III Clinical Trials
- First-In-Class Drug RGRN-305 (BEBT-305) Clinical Proof-of-Concept Study Results ...
- First-In-Class Drug BEBT-908 Research Results of BEBT-908 Published on CANCER RE...
- BeBetter Med’s BEBT-908 granted Breakthrough Therapy designation
